Ricerc@Sapienza

Aims: Incidence, associated risk factors and impact on mortality of infections after bypass surgery (CABG) and stenting (PCI) for multivessel coronary disease (MVD) have never been reported in a large randomised trial. The aim of the present study was to evaluate, in patients with MVD, the prevalence of major infections after PCI and CABG and to assess their impact on mortality. Methods and results: The SYNTAX trial randomised 1,800 MVD patients to either CABG or PCI. Patients were followed up to five years.

Background/Aim: Non-small cell lung cancer (NSCLC) is the leading cause of cancer death. Patients eligible for surgery have better overall survival rate than patients who are not eligible. We investigated the prognostic value of p16 in patients who underwent surgery for lung cancer, in association with other factors such as PD-L1 and Ki-67. Materials and Methods: Expression of p16 was evaluated along with the presence of Ki-67 and PD-L1 in 256 NSCLC patients treated only surgically.

urs in the elderly population, sometimes in an
advanced stage, when intensive treatments are needed.
Radiotherapy can achieve high response rates. We evaluated
efficacy and tolerability of hypofractionated radiotherapy in
a population of very elderly patients with locally advanced
epithelial skin cancer. Patients and Methods: Two different
hypofractionated schedules were administered (21 patients):
6 Gy in 10 bi-weekly fractions (13 lesions) and 5 Gy in 12
bi-weekly fractions (13 lesions). Median age at treatment was

Abstract
BACKGROUND/AIM:

To evaluate outcomes in patients with low-risk prostate cancer treated with hypofractionated radiotherapy (HyRT).
PATIENTS AND METHODS:

Between April 2004 and December 2015, 175 patients with low-risk prostate cancer were treated with HyRT 60 Gy in 20 fractions with or without image guidance and reduction of margin from clinical target volume to planning target volume.
RESULTS:

In this study, we evaluated if surgical treatment and iterative operations could confer a survival advantage for patients with recurrent or repeated recurrences of thymoma.